First-in-man implantation of a pre-packaged self-expandable dry-tissue transcatheter aortic valve

Feng, Yu; Zhang, Zhengang; Baccaro, Jorge A.; Zeng, Min Frank; Fish, R. David; Chen, Mao

doi:10.1093/eurheartj/ehx587

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New device trials include a clinical evaluation of the Vascular Innovations Co. Ltd. HYDRA self‐expanding transcatheter aortic valve (http://clinicaltrials.gov Identifier: NCT02434263; Thubrikar Aortic Valve Inc., 2019), and the Colibri heart valve clinical investigation (“COL‐01”), a study (http://clinicaltrials.gov Identifier: NCT04029844; Colibri Heart Valve LLC, 2019) for CE marking in high surgical risk patients. Other devices still in preliminary phases or under development outside Europe include: Venus Medtech (Hangzhou) Inc Venus A‐valve (Liao et al, 2017), JC Medical J‐Valve (Zhu et al, 2018; Hensey et al, 2019), MicroPort VitaFlow (Zhou et al, 2020), Peijia Medical TaurusOne, Venibri Valve (Feng et al, 2018), Xeltis endogenous tissue restoration aortic valve (Miyazaki et al, 2017), Zurich tissue‐engineered heart valves (TEHV; Lintas et al, 2018), SAT (Strait Access Technologies, Cape Town, South Africa) self‐homing, non‐occlusive balloon‐expandable TAVI system for rheumatic heart disease (Scherman et al, 2019), Polynova polymeric aortic valve TAVI (Rotman et al, 2019), and Corlife oHG's decellularized human aortic valve Arise AV (Horke et al, 2020).…”

Section: Outlooksmentioning

confidence: 99%

A European update on transcatheter aortic valve implantation (TAVI) in the COVID era

Antony¹,

Abraha

Hameed

et al. 2022

Journal of Anatomy

View full text Add to dashboard Cite

The global burden of aortic valvular disease is increasing worldwide due to an increase in the aging population (Coffey et al., 2021).Conventional treatment of aortic valve disease typically involves surgical aortic valve replacement (SAVR), wherein the degenerated aortic valve cusps are excised completely to allow for surgical implantation of a prosthetic valve (Walther et al., 2012). Surgical cardiac intervention requires access to the thoracic cage, via a limited access incision but often it necessitates a median sternotomy. Thus, SAVR is precluded to patients at risk for surgery, such as those with prior surgical complications, chest wall anatomical defects, porcelain aorta, severe pulmonary hypertension, severe right ventricular dysfunction, frailty, radiation damage, severe liver disease, impaired renal function, diabetes mellitus, and severe lung disease (Kappetein et al., 2012). Transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR) is fast emerging as an alternative intervention for this patient cohort. TAVI or TAVR is a minimally invasive, cost-effective (Mennini et al., 2022;Reynolds et al., 2012;Watt et al., 2012), a procedure wherein a prosthetic valve is implanted within the existing native aortic valve, without removal of the old damaged tissue. The new prosthetic valve is typically deployed via the transfemoral route, though other approaches include transapical, subclavian, direct aortic, and transcaval access. The first use of TAVI in humans took place in 2002 with the implantation of a balloon-expandable, stainless steel stented bovine pericardial aortic valve developed by Percutaneous Valve Technologies (later acquired by Edwards Lifesciences; Cribier et al., 2002). CoreValve (later acquired by Medtronic in 2009) followed with their self-expandable, nitinol stented bovine pericardial aortic valve prosthesis, with the first successful human implants in 2005 (Grube et al., 2005). Newer generations of these valves currently exist and other devices are entering the market currently indicated for certain populations or

show abstract

Section: Outlooksmentioning

confidence: 99%

A European update on transcatheter aortic valve implantation (TAVI) in the COVID era

Antony¹,

Abraha

Hameed

et al. 2022

Journal of Anatomy

View full text Add to dashboard Cite

show abstract

“…On the basis of the retrievable function, the Venus A pilot adds an adjustable bending function to ensure the coaxiality of the valve release. Qiming Venibri Valve is the world's first preinstalled TAVI valve, so that the valve can be used in the catheterization room, saving valuable time for critically ill patients to save lives [46].…”

Section: The Development Of Tavi Technology In Chinamentioning

confidence: 99%

Transcatheter Treatment of Aortic Stenosis and Regurgitation

Zhang¹,

Xu²

2021

Advances in Complex Valvular Disease

View full text Add to dashboard Cite

Since the successful application of transcatheter aortic valve implantation (TAVI) in 2002, the interventional treatment of valvular heart disease has developed rapidly. The interventional treatment of aortic valve stenosis or insufficiency has been more mature, and many new-generation TAVI valves have been developed. The recommended level of TAVI technology in the European and American heart valve disease guidelines has increased year by year. In 2019, the multi-center randomized controlled study on patients with low-risk aortic stenosis and conventional aortic valve replacement also showed the advantages of interventional treatment technology, such as small trauma, fast recovery and less complications, and better hemodynamics, which greatly promoted the development of TAVI technology.

show abstract